Health and Healthcare

All Health and Healthcare Articles

Newest first · Page 363

Glaxo (GSK) CEO Has A Senior Moment

GlaxoSmithKline’s (GSK) diabetes drug Avandia has such frightening side effects that the FDA will probably make it carry a "black box" label. Studies have found that the treatment can increase risk of heart attack.…

Douglas A. McIntyre · 19 years ago

Vioxx: Merck (MRK) Settled Too Early, Much Too Early

It has been a bloody and bitter fight. Merck’s (MRK) pain killer Vioxx has been alleged to cause heart problems and worse. The drug hit the market in 1999 and was pulled in 2004.…

Douglas A. McIntyre · 19 years ago

Allscripts… Just When You Thought It Was Safe (MDRX)

Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) is trading at a new 52-week low after a disaster earnings report this afternoon.  Non-GAAP adjusted earnings for the quarter ended September 30, were $6.7 million, or $0.11 per…

Douglas A. McIntyre · 19 years ago

Geron Positive Spinal Cord Injury Data (GERN)

Geron Corp. (NASDAQ:GERN) is trading up in pre-market activity on news that would have been much more eagerly received back in the emergence of stem cell news.  Geron announced that data shows its human…

Douglas A. McIntyre · 19 years ago

Glaxo Avandia Sales Appear To Be Vanishing (GSK)

GlaxoSmithKline’s (NYSE:GSK) Avandia sales might not just weak after the reports of cardiovascular risks were reported.  If this research is accurate, the sales might be on the path to vanishing.  We have not conducted…

Douglas A. McIntyre · 19 years ago

GTX Soaring On Merck Collaboration (GTXI, MRK)

GTx, Inc. (NASDAQ: GTXI) is seeing shares trade sharply higher on a collaboration pact with Merck (NYSE: MRK).  The biotech and drug giant pact is for research and development and a strategic collaboration for…

Douglas A. McIntyre · 19 years ago

Biotech Implosion: Novacea (NOVC, SGP)

Novacea, Inc. (NASDAQ:NOVC) has ended its Phase III ASCENT-2 clinical trial of Asentar(TM) (DN-101).  Unfortunately this is Novacea’s lead investigational cancer therapy for the treatment of patients with androgen-independent prostate cancer. The trial halt…

Douglas A. McIntyre · 19 years ago

A Little Trouble For Bristol-Myers (BMY) Plavix

Plavix from Bristol-Myers (BMY) is the medical drug-thinner of choice. According to CNN Money, sales of the drug "totaled $3.4 billion in sales during the first nine months"  Now Eli Lilly (LLY) has a…

Douglas A. McIntyre · 19 years ago

Pfizer (PFE): Viagra Can Make Men Hard Of Hearing

Pfizer (PFE) has a new ad campaign for its erectile dysfunction drug Viagra. The marketing message is all over TV and in little video clips online. Reuters.com appears to have one of the ads…

Douglas A. McIntyre · 19 years ago

Cramer Defends Nastech After Weakness (NSTK)

On tonight’s MAD MONEY on CNBC, Jim Cramer said he has a small speculative stock that got crushed.  Nastech Pharmaceutical Inc. (NASDAQ:NSTK) is supposed to win from an intranasal delivery system, and it is…

Douglas A. McIntyre · 19 years ago

Deciphering Medarex Earnings (MEDX)

Some traders might bother peering at the losses on Medarex (NASDAQ:MEDX), but all we are looking at for the time being is the forward study data and the company’s use of cash and burn…

Douglas A. McIntyre · 19 years ago

WellCare Analyst Hopes….. Either Genius Or Just Crazy (WCG)

Shares of WellCare Health Plans (NYSE:WCG) are up marginally in pre-market trading Monday. Jefferies & Co. issued a report that, despite the FBI raids, the company probably won’t lose its Medicare contracts even though…

Douglas A. McIntyre · 19 years ago